Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

Ocella, Yasmin, YAZ, Gianvi, Beyaz, And Safyral Can Cause Pulmonary Embolism, Deep Vein Thrombosis, Stroke, And Heart Attack

These Popular Birth Control Pills Contain Drospirenone (DRSP), Which Is A Possibly Dangerous Progestin Not Used In Any Other Contraceptive

The popular birth control pills YAZ and Yasmin both contain the progestin drospirenone (DRSP). These pills are differentiated by the amount of the estrogen ethinyl estradiol each contains -- YAZ has a 20-mcg dose (as does Gianvi, a generic version of YAZ) while the older Yasmin has a 30-mcg dose (as does Ocella, a generic versions of Yasmin).

Beyaz contains the same estrogen-progestin combination as YAZ plus 0.451 mg of levomefolate calcium.

Safyral contains the same estrogen-progestin combination as Yasmin plus 0.451 mg of levomefolate calcium.

Because Ocella, Yasmin, YAZ, Gianvi, Beyaz, and Safyral contain DRSP, these birth control pills have been linked to venous thromboembolic (VTE) events such as pulmonary embolism (PE) and deep vein thrombosis (DVT) as well as ischemic stroke (CVA) and myocardial infarction (MI), or heart attack.

Two medical journal articles published in August 2009 offer some insight about: first, the extent of increased risk of thromboembolisms -- PE, DVT, CVA, and MI -- in women using Ocella, Yasmin, YAZ, Gianvi, Beyaz, or Safyral; and, second, how drospirenone (DRSP) may be responsible for these serious side effects.

We start with the article "The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestogen type: results of the MEGA case-control study", which was published by the medical journal BMJ on August 13, 2009.

This BMJ article provides the results of a case-control study among premenopausal women under 50 at six clinics in the Netherlands. In relevant part, the Dutch researchers found that oral contraceptives (OCs) which contained the progestin levonorgestrel carried a 3.6-fold increased risk of venous thrombosis -- PE, DVT, CVA, and MI -- whereas birth control pills with dropspirenone (DRSP) -- Ocella, Yasmin, YAZ, Gianvi, Beyaz, and Safyral -- had a 6.3 fold increased risk.

Put another way, when levonorgestrel-containing OCs were compared with Ocella, Yasmin, YAZ, Gianvi, Beyaz, and Safyral -- birth control pills with DRSP -- the risk of thrombosis associated with the DRSP pills was found to be about 1.7 times greater than the levonorgestrel OCs.

Next we turn to the Abstract for this August 2009 article, "Effects of oral contraception with ethinylestradiol and drospirenone on oxidative stress in women 18-35 years old.", which was published in the Contraception medical journal:

BACKGROUND: Oral contraceptives (OCs) with estrogens and progestins may affect oxidative stress (OS) status.

STUDY DESIGN: A group of 32 women using oral contraceptives (OCU) containing 0.03 mg ethinylestradiol and 3 mg drospirenone [i.e., Yasmin and its generic versions Ocella and Zarah] have been compared to a matched control group of 30 noncontraception users (NCU).

CONCLUSIONS: The recently introduced combination of ethinylestradiol and drospirenone induced the heightening of lipid peroxidation correlated with high levels of copper, a situation that could be associated with increased cardiovascular risk.

For more information about the apparent increased risks of pulmonary embolism (PE), deep vein thrombosis (DVT), stroke (CVA), and heart attack (MI) when estrogen is combined with the progestin drospirenone (DRSP), you may want to see our article "How And Why YAZ, Yasmin, Ocella, Gianvi, Beyaz, And Safyral Pills Might Cause A Higher Rate Of Blood Clots In Women".

Go to Free Case Evaluation form >>

Read more on our Drospirenone (DRSP) Birth Control Pills Information Page >>


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer